SCHEMBL352642

SCHEMBL352642

CN(Cc1csc(NC(=O)NCc2ccc(Cl)s2)n1)C(=O)c1cccnc1N1CCOCC1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.38
KLKB1 P03952 2/20 0.36
HCAR1 Q9BXC0 2/20 0.36
EPHX2 P34913 1/20 0.36
KIF18A Q8NI77 1/20 0.36
SCN10A Q9Y5Y9 2/20 0.35
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35
ROCK2 O75116 1/20 0.35
ROCK1 Q13464 1/20 0.35
F2 P00734 1/20 0.34
HCAR2 Q8TDS4 1/20 0.34
TPH1 P17752 1/20 0.34
ALDH1A1 P00352 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SCN2A Q99250 1/20 0.34
PIK3CA P42336 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL353345 0.94 EPHX2 (0.37) NAMPTEPHX2RAB9ANPC1ROCK2
SCHEMBL353566 0.88 NAMPT (0.38) NAMPTKLKB1HCAR1EPHX2KIF18A
SCHEMBL352905 0.85 ROCK2 (0.47) NAMPTROCK2ROCK1
SCHEMBL354215 0.82 TSHR (0.35) NAMPTKLKB1EPHX2SCN10AF2
SCHEMBL353550 0.78 ROCK2 (0.49) NAMPTROCK2ROCK1ALDH1A1SMN1; SMN2
SCHEMBL352881 0.77 KMT2A (0.40) RAB9ANPC1ROCK2ROCK1F2
SCHEMBL355250 0.77 KMT2A (0.38) RAB9ANPC1ROCK2ROCK1F2
SCHEMBL353459 0.76 KMT2A (0.38) RAB9ANPC1ROCK2ROCK1F2
SCHEMBL352646 0.75 F10 (0.33) RAB9ANPC1ROCK2ROCK1F2
SCHEMBL354863 0.74 KMT2A (0.39) RAB9ANPC1ROCK2ROCK1F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP claimed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US claimed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US claimed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 EP claimed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO claimed
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP disclosed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US disclosed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US disclosed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 EP disclosed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds NAAA, AADAC, RPSA NAMPT 262/4885KLKB1 4776/4885HCAR1 3001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.